Amgen’s lupus bets continue to flounder, even those on the Horizon

Amgen’s lupus pursuits have encountered another pitfall, this time via recently-purchased Horizon Therapeutics. 

Horizon reported that its lupus candidate daxdilimab did not produce a meaningful difference in assessment of disease activity compared to placebo, according to results announced late Friday. The biotech said “numerical differences” were identified in other endpoints in the phase 2 trial and that no safety concerns were reported.